Ascendis Pharma A/S expected to post a loss of €1.50 a share - Earnings Preview

Ascendis Pharma A/S

23/04/2024 23:14

* Ascendis Pharma A/S  ASND.OQ   ASND.O  is expected to show
a
rise in quarterly revenue when it reports  results on April 25
(estimated) for the period ending March 31 2024
    * The Hellerup Denmark-based   company is expected to report
a
136.7% increase in revenue to €79.492 million from €33.59
million a year ago, according to the mean estimate from 11
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Ascendis Pharma A/S is
for a
loss of €1.50 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 5.2%
in the last three months. ​
    * Wall Street's median 12-month price target for Ascendis
Pharma
A/S is $171.76​, above​ its last closing price of $142.10. ​​​

Previous quarterly performance (using preferred earnings measure
in euros). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -1.98       -2.03      -1.54     Beat    24
 Sep. 30 2023  -2.32       -2.38      -2.88     Missed  -21.1
 Jun. 30 2023  -2.57       -2.59      -2.16     Beat    16.6​
 Mar. 31 2023  -2.65       -2.66      -1.98     Beat    25.6
 ​​Dec.        -2.44       -2.56      -3.70     Missed  -44.5
 31 2022                                                
 Sep. 30 2022  -2.49       -2.49      -3.03     Missed  -21.7​
 Jun. 30 2022  -2.08       -2.13      -1.46     Beat    31.5
 Mar. 31 2022  -1.98       -2.00      -2.21     Missed  -10.5
 This summary was machine generated April 23 at 22:14 GMT.  All
figures in euros unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)